ARTA
EVFM

A.R.T. Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

A.R.T. Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-203
Closed -$20K – 1805
2016
Q4 		$20K Buy
+203
New +$21.1K ﹤0.01% 1244
2016
Q3 		– Sell
-212
Closed -$18K – 1307
2016
Q2 		$18K Sell
212
-429
-67% -$38.4K ﹤0.01% 1307
2016
Q1 		$35K Buy
641
+284
+80% +$22K ﹤0.01% 1300
2015
Q4 		$44K Buy
357
+95
+36% +$62.6K ﹤0.01% 1386
2015
Q3 		$190K Buy
+262
New +$281K 0.01% 1176

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

A.R.T. Advisors's EVFM Position: Q1 2017 in Review

A.R.T. Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q1 2017, closing a stake of 203 shares — an estimated $20K sold.

A.R.T. Advisors first reported a position in EVFM in Q3 2015 and held it in 5 quarters. The position peaked at $190K in Q3 2015. 16 funds tracked by Wall St. Rank hold EVFM as of Q1 2017.

  • A.R.T. Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 203 Evofem Biosciences, Inc. Common Stock shares in Q1 2017, an estimated $20K.
  • A.R.T. Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2015 and held it in 5 quarters.
  • A.R.T. Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $190K in Q3 2015.
  • 16 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q1 2017.

Based on A.R.T. Advisors's 13F filing for Q1 2017, filed 15 May 2017.